Disc Medicine (NASDAQ:IRON) CFO Sells $24,378.18 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) CFO Jean Franchi sold 353 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $69.06, for a total value of $24,378.18. Following the sale, the chief financial officer directly owned 70,990 shares of the company’s stock, valued at $4,902,569.40. The trade was a 0.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Disc Medicine Stock Performance

Shares of NASDAQ:IRON traded down $1.29 during trading on Friday, reaching $66.62. The company had a trading volume of 345,062 shares, compared to its average volume of 762,160. Disc Medicine, Inc. has a fifty-two week low of $30.82 and a fifty-two week high of $99.50. The company has a debt-to-equity ratio of 0.05, a current ratio of 23.45 and a quick ratio of 23.45. The stock’s fifty day moving average price is $74.70 and its 200 day moving average price is $75.34. The firm has a market capitalization of $2.51 billion, a price-to-earnings ratio of -12.45 and a beta of 0.88.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($1.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.69) by $0.07. As a group, equities research analysts predict that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on IRON. Raymond James Financial restated a “market perform” rating on shares of Disc Medicine in a research report on Thursday, January 15th. BMO Capital Markets reduced their price target on Disc Medicine from $120.00 to $100.00 and set an “outperform” rating for the company in a report on Tuesday, February 17th. Cantor Fitzgerald dropped their price objective on Disc Medicine from $153.00 to $125.00 and set an “overweight” rating on the stock in a report on Tuesday, February 17th. Truist Financial cut their price objective on Disc Medicine from $114.00 to $83.00 and set a “buy” rating for the company in a research report on Friday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research report on Wednesday, January 21st. Eleven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $102.00.

Institutional Trading of Disc Medicine

Several large investors have recently bought and sold shares of the company. Arizona State Retirement System increased its position in shares of Disc Medicine by 1.8% in the third quarter. Arizona State Retirement System now owns 6,654 shares of the company’s stock valued at $440,000 after buying an additional 120 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Disc Medicine by 2.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,094 shares of the company’s stock valued at $469,000 after acquiring an additional 138 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in Disc Medicine by 8.9% during the second quarter. Ameritas Investment Partners Inc. now owns 2,515 shares of the company’s stock worth $133,000 after acquiring an additional 206 shares during the last quarter. Police & Firemen s Retirement System of New Jersey raised its position in Disc Medicine by 3.3% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 6,716 shares of the company’s stock worth $533,000 after acquiring an additional 215 shares during the last quarter. Finally, Avanza Fonder AB lifted its holdings in shares of Disc Medicine by 14.1% in the fourth quarter. Avanza Fonder AB now owns 1,903 shares of the company’s stock valued at $151,000 after purchasing an additional 235 shares in the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.